Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients aged 2 years and older with advanced or metastatic medullary thyroid cancer, an FDA test-confirmed RET mutation and a need for systemic therapy.
LAMPGEN ANALYSIS
Why it matters
This traditional approval confirmed the medullary thyroid cancer indication after a randomized comparison against standard kinase inhibitors.
What research teams should watch
Record the exact RET alteration and age, and track what evidence comes from the adult/adolescent trial versus the pediatric data.
PRIMARY RECORDS